Patents
Literature
6 results about "RNase P" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ribonuclease P (EC 3.1.26.5, RNase P) is a type of ribonuclease which cleaves RNA. RNase P is unique from other RNases in that it is a ribozyme – a ribonucleic acid that acts as a catalyst in the same way that a protein-based enzyme would. Its function is to cleave off an extra, or precursor, sequence of RNA on tRNA molecules. Further, RNase P is one of two known multiple turnover ribozymes in nature (the other being the ribosome), the discovery of which earned Sidney Altman and Thomas Cech the Nobel Prize in Chemistry in 1989: in the 1970s, Altman discovered the existence of precursor tRNA with flanking sequences and was the first to characterize RNase P and its activity in processing of the 5' leader sequence of precursor tRNA. Recent findings also reveal that RNase P has a new function. It has been shown that human nuclear RNase P is required for the normal and efficient transcription of various small noncoding RNAs, such as tRNA, 5S rRNA, SRP RNA and U6 snRNA genes, which are transcribed by RNA polymerase III, one of three major nuclear RNA polymerases in human cells.
Digital PCR kit and method for accurately detecting copy number of CAR gene of CAR-T cell and lentiviral vector
PendingCN122256493AMicrobiological testing/measurementDNA/RNA fragmentationDiseaseMolecular diagnostic techniques
The application belongs to the technical field of molecular diagnosis, and particularly relates to a digital PCR kit and method for accurately detecting the copy number of a CAR gene of a CAR-T cell and a lentivirus vector. The application first realizes the absolute quantification of CAR, Rev and an internal reference gene RNase P in a single tube simultaneously, and has strong universality. Based on the principle of digital PCR, the absolute copy number is directly obtained without a standard curve, and the result is accurate and highly repeatable. The detection lower limit reaches 0.01%, and extremely low abundance CAR-T residues or microresidual diseases can be detected. Primers and probes are designed for the conservative regions of CD3zeta, Rev and RNase P, and no cross reaction is verified, so that false positives are effectively avoided. The sample only needs gDNA, and there is no requirement for cell activity, and the sample is compatible with freezing and transportation. The kit is premixed and optimized, the process is automated, and 4-5 hours are needed. The kit is suitable for the whole chain of CAR-T drug research and development, production process quality control, clinical patient monitoring and safety evaluation.
Owner:HANGZHOU DIAN BIOTECH CO LTD
A composition for detecting mycobacterium tuberculosis complex and use thereof
PendingCN122146905AMicrobiological testing/measurementMicroorganism based processesTuberculosis mycobacteriumNon tuberculosis mycobacterium
The application belongs to the technical field of molecular biology detection, and particularly relates to a composition for detecting mycobacterium tuberculosis complex and application thereof. The application provides a primer pair and a probe for detecting mycobacterium tuberculosis complex, and simultaneously uses IS6110 and IS1081 genes specific to the mycobacterium tuberculosis complex as detection targets, and introduces a RNase P endogenous internal standard gene fragment, and the primer and the probe are respectively designed according to the conservative sequences of the IS6110 and IS1081 genes of the mycobacterium tuberculosis complex, and the primer and the probe have good accuracy, specificity and sensitivity for detecting the mycobacterium tuberculosis complex. The results of the examples show that the detection accuracy of the primer pair and the probe provided by the application for the mycobacterium tuberculosis complex can reach 100%, and no fluorescence signal is found for detecting other non-mycobacterium tuberculosis species.
Owner:BASO DIAGNOSTICS INC ZHUHAI
Triple fluorescent PCR (Polymerase Chain Reaction) nucleic acid detection kit for monkey pox virus, detection method and application
PendingCN121874400AMicrobiological testing/measurementMicroorganism based processesGene FeatureSample quality
The invention discloses a monkey pox virus triple fluorescence PCR nucleic acid detection kit, a detection method and application. The kit adopts a single-tube triple detection system and comprises (a) a monkey pox virus universal detection primer probe group and a targeted F3L and G2R gene conserved region; (b) a Clade Ib subtype detection primer probe group which targets D14L and A36R gene deletion feature regions; (c) a Clade II subtype detection primer probe group, which is used for targeting J2R and D18L gene feature sequences; and (d) an internal standard detection group which targets the human RNase P gene. By optimizing the concentrations of the primers and probes and four-channel fluorescent labels (FAM universal type, VI-Clade Ib, ROX-Clade II and CY5 internal label), single-tube synchronous detection is realized. The leak detection risk is reduced by adopting a double-target redundancy design, virus screening and subtype identification (Clade Ib / II) can be completed through single detection, and an internal standard system monitors the quality of a sample in the whole process. The kit is suitable for clinical early diagnosis, epidemic prevention and control and strain traceability.
Owner:HANGZHOU INT TRAVEL HEALTH CARE CENT (HANGZHOU CUSTOMS PORT CLINIC) +1
Identification of inhibitors of the catalytic RNA subunit of rnase p
PCT designated stageWO2026064652A9Organic active ingredientsAntibacterial agentsCatalytic RNAChemical compound
The present invention demonstrates the utility of small-molecule microarray (SMM) screening method used to identify novel small-molecule scaffolds that bind to long non-coding RNAs (lncRNAs), thereby expanding the possibilities for RNA-targeted therapeutics. RNase P is a ribozyme that is essential for 5'-maturation of precursor tRNAs. Disclosed herein is an inhibitor of the Methanobrevibacter smithii RNase P RNA (Msm RPR). The inhibitor comprises of a diaryl-piperidine compound, termed M1, to inhibit Msm RPR. Given the similarity of Msm RPR to RPRs from similar archaea in the rumen, the present invention provides support for the idea of mitigating methane production by altering rumen tRNA metabolism.
Owner:OHIO STATE INNOVATION FOUND +2
Identification of inhibitors of the catalytic RNA subunit of rnase p
PCT designated stageWO2026064652A1Organic active ingredientsAntibacterial agentsCatalytic RNAChemical compound
The present invention demonstrates the utility of small-molecule microarray (SMM) screening method used to identify novel small-molecule scaffolds that bind to long non-coding RNAs (lncRNAs), thereby expanding the possibilities for RNA-targeted therapeutics. RNase P is a ribozyme that is essential for 5'-maturation of precursor tRNAs. Disclosed herein is an inhibitor of the Methanobrevibacter smithii RNase P RNA (Msm RPR). The inhibitor comprises of a diaryl-piperidine compound, termed M1, to inhibit Msm RPR. Given the similarity of Msm RPR to RPRs from similar archaea in the rumen, the present invention provides support for the idea of mitigating methane production by altering rumen tRNA metabolism.
Owner:OHIO STATE INNOVATION FOUND +2
CDI enhanced COVID-19 test
A detection panel for the universal detection of SARS-like coronaviruses and SARS-CoV-2 viruses and a method for using the detection panel are provided. The detection panel may be known as a Center for Discovery and Innovation (“CDI”) detection panel (CDI Enhanced COVID-19 Test) and may also include an additional primer / probe set in the detection panel to detect the human RNase P gene (RP) in control samples and clinical specimens. The detection panel is designed for both universal detection of SARS-like coronaviruses using an E gene (envelope) detection assay, and specific detection of the SARS-CoV-2, using an N2 (nucleocapsid) detection assay.
Owner:HACKENSACK MERIDIAN HEALTH INC